Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma.
Persico
Marcello
M
De Marino
Fedele
F
Russo
Giovanni Di Giacomo
GD
Morante
Aristide
A
Rotoli
Bruno
B
Torella
Roberto
R
De Renzo
Amalia
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015897:Comorbidity; D004341:Drug Evaluation; D005260:Female; D016174:Hepacivirus / Q000187:drug effects / Q000502:physiology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000453:epidemiology; D006526:Hepatitis C / Q000150:complications / Q000453:epidemiology; D006801:Humans; D016867:Immunocompromised Host; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use*; D008111:Liver Function Tests; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects*; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine